comparison of oral recombinant erythropoietin and subcutaneous recombinant erythropoietin in prevention of anemia of prematurity

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity

BACKGROUND Premature neonates are at risk for severe anemia and erythropoietin is the most important hormone in erythropoiesis. The aim of this study was to evaluate the influence of oral recombinant human erythropoietin (rhEPO) in proving erythropoiesis in neonates. METHODS This was a randomized clinical trial study. Thirty neonates were enrolled from September 2007 to September 2008. The fi...

Recombinant Human Erythropoietin in Cancer-Related Anemia

The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of oncology. A decade ago, randomized, placebo-controlled trials in anemic cancer patients demonstrated that rHuEPO resulted in an improvement in hemoglobin and hematocrit, a reduction in transfusion requirements, and improvement in quality-of-life (QOL) end points. Based o...

Recombinant Human Erythropoietin in Children with Solid Tumors and Chemotherapy-induced Anemia

Background: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of chemotherapy-induced anemia is crucial. This study was aimed to evaluate the efficacy of recombinant human erythropoietin in reducing the need for blood transfusion in children with sol...

[The effect of recombinant human erythropoietin on the treatment of anemia of prematurity]

OBJECTIVE: To assess the efficacy of erythropoietin in the prevention and treatment of anemia of prematurity, correlating the use of this drug with weight gain, length, and head circumference and comparing two administration schemes of he same weekly dose: daily use and twice a week. METHODS: The study comprised 42 premature newborns with gestational age up to 33 weeks, birthweight up to 1550 g...

Development of Radiolabeled Recombinant Erythropoietin for Receptor Studies

Effects of Recombinant Human Erythropoietin (rHuEpo) on the Blood Cells and Hematopoiesis in Spleen of Rats

Recombinant human erythropoietin is a glycoprotein hormone that stimulates erythropoiesis. In clonogenic assays of hematopoietic progenitors, high concen-trations of erythropoietin (Epo) increase CFU-E and diminish the number of granulocytes formed per culture plate. Fetal progenitors are more sensitive to these effects of Epo than progenitors from adults. We administered doses 50, 100, 200 IU/...